- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00706615
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
A Single Arm Open-Label Phase I Study of An Injectable Replication-Incompetent Adenoviral Vector Vaccine Used to Produce An Immune Response to MUC-1 Positive Epithelial Cancer Cells in Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated metastatic breast cancer.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- Characterize the safety profile of Ad-sig-hMUC-1/ecdCD40L vaccine in women with metastatic breast cancer.
- Identify a tolerable, immunologically active dose level of this vaccine in these patients.
Secondary
- Evaluate the immune function in these patients before and after treatment with this vaccine.
OUTLINE: Patients receive MUC-1 vector vaccine subcutaneously on day 0.
After completion of study treatment, patients are followed monthly for 9 months.
Studietype
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90095-1781
- Jonsson Comprehensive Cancer Center at UCLA
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Women over the age of 18 with metastatic or non-measureable adenocarcinoma of the breast with marrow involvement.
- Elevated serum MUC-1 levels, as measured by CA 15-3 or CA 27-29
- Stable disease (defined as fluctuation of <50U in CA15-3 or CA27-29 value) for at least 3 months while either on no breast-cancer therapy or while on current therapy (Tamoxifen, fulvestrant, exemestane, letrozole, anastrozole, bisphosphonates or trastuzumab chemotherapy is not allowed)
- ability to understand the risks, benefits, and procedures and provide written informed consent.
- less than 28 days prior to enrollment since last surgery and/or radiation therapy.
- performance status <=2 on the ECOG performance scale and life expectancy of greater than 12 months
- NYHA cardiac function Class I or Class II and normal baseline ECG. If ECG is abnormal, patient must have an echocardiogram showing a left ventricular ejection fraction greater than the lower limits of normal.
- patients who do not have radiographically assessable locally recurrent or metastatic disease are eligible if they 1) had radiographic or biopsy proven locally recurrent or metastatic breast cancer in the past and 2) currently (at study entry) have an elevated serum MUC-1 level (as measured by CA 15-3 or CA 27-29).
- Acceptable pulmonary function. if questionable, a pulmonary function test will be performed.
- negative serology for hepatitis B, C and HIV.
- red cell mean corpuscular volume >- 80 cu. mm, hemoglobin >- 8g/dl, platelet count >- 100,000/dl: AST, ALT, LDH <-2 times the Upper limit of normal
- Serum creatinine < 1.6 mg/dL
- for women with child bearing potential, Negative urine pregnancy test within 7 days of registration and willingness to use an approved contraceptive method while participating in this trial.
Exclusion Criteria:
- history of bronchospasm or asthma requiring inhaled or oral steroid treatment
- Normal MUC-1 (CA 15-3 or CA 27-29)
- treatment with steroid or other immunosuppressive medication (for any condition ) within 30 days of trial registration.
- history of any autoimmune disease (e.g., lupus, rheumatoid arthritis, or psoriasis)
- uncontrolled diabetes mellitus
- unable or unwilling to undergo repeated clinical evaluations and other diagnostic procedures or unable to sign an informed consent.
- history of other malignancies, except squamous cell or basal cell carcinoma of the skin or cervical carcinoma in situ.
- Concurrent systemic chemotherapy (tamoxifen, aromatase inhibitors, fulvestrant, trastuzumab and biophosphonates are allowed if started more than 3 months prior to trial registration with evidence of stable disease as defined above. Chemotherapy must have stopped 3 months prior to enrolling in this trial).
- history of ornithine transcarbamylase deficiency
- any acute or chronic viral, bacterial, or fungal infection requiring specific therapy, unless acute therapy was completed within the past 14 days
- No underlying conditions that would contraindicate therapy with study treatment ( or allergies to reagents used in this study)
- history of organ transplant or allogeneic bone marrow transplant
- life threatening or organ-threatening disease expected to require conventional therapy within 4 months.
- pregnant or nursing females.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Masker: Geen (open label)
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
---|
Characterize the safety profile of the Ad-sig-hMUC-1/ecdCD40L vector vaccine
|
Identification of a tolerable, immunologically active dose level
|
Secundaire uitkomstmaten
Uitkomstmaat |
---|
Assess efficacy based on serum MUC-1 level
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Sara Hurvitz, MD, Jonsson Comprehensive Cancer Center
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CDR0000599060
- UCLA-07-05-056
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op Ad-sig-hMUC-1/ecdCD40L vaccine
-
Singapore Clinical Research InstituteClinDatrix, Inc.; MicroVAX, LLCOnbekendEpitheliale kankers van de longen, borsten, eierstokken, prostaat en dikke darmSingapore
-
Sun Yat-sen UniversitySun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Zhujiang Hospital; Guangzhou...Nog niet aan het werven